Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

NCT05877430 is registered in ClinicalTrials.gov with CJ Bioscience, Inc. as lead sponsor.

NCT NCT05877430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05877430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Lead sponsor
CJ Bioscience, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 11, 2023
Completion date
October 31, 2027
Enrollment
160 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, hnscc, melanoma, metastatic cancer, nsclc